Rasch Analysis of the Independent Mobility Questionnaire

Fenwick, Eva; O’Hare, Fleur; Deverell, Lil; Ayton, Lauren N; Luu, Chi D; McSweeney, Shane; Bentley, Sharon A; Guymer, Robyn H.; Finger, Robert P.

doi:10.1097/opx.0000000000000787

Cited by 5 publications

(4 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Ultimately, 64 publications and 7 reviews (71 publications) were identified from the literature relating to 41 different QoL questionnaires (general health, vision-specific and glaucoma-specific questionnaires) which were included in the qualitative analysis (see Table, Supplemental Digital Content 3, which lists the 41 QoL questionnaires included in the analysis, http://links.lww.com/IJG/A562). 15,28–81…”

Section: Resultsmentioning

confidence: 99%

A Scoping Review of Quality of Life Questionnaires in Glaucoma Patients

Gazzard

Kolko

Iester

et al. 2021

Journal of Glaucoma

View full text Add to dashboard Cite

show abstract

Section: Resultsmentioning

confidence: 99%

A Scoping Review of Quality of Life Questionnaires in Glaucoma Patients

Gazzard

Kolko

Iester

et al. 2021

Journal of Glaucoma

View full text Add to dashboard Cite

show abstract

“…A flow diagram of our systematic review is included in the supplementary material. Raw data were provided for studies conducted at the Centre for Eye Research Australia (CERA, Melbourne, Vic., Australia) [62], the University of Derby (Derby, UK) [34], and at Veterans Affairs Medical Center, Salisbury, NC (VASNC) [25]. Data were also available for two studies in which some of the authors had been engaged: one study conducted at Massachusetts Eye and Ear Infirmary (MEEI), Boston, MA [3,4,57]; and one conducted at the Schepens Eye Research Institute (SERI), Boston, MA [40].…”

Section: Study Populationmentioning

confidence: 99%

“…There were no significant differences in gender [Pearson χ 2 (4, N = 594) = 8.92, p = 0.06] between the five data sources. However, there was a significant difference in age [Kruskal Wallis, χ 2 (4, N = 594) = 103.8, p < 0.001], with the CERA [62] sample being older than the SERI [40] sample (regression; t = 2.32; p = 0.021), which was older than the Derby sample (t = 2.59; p = 0.01) and VASNC [25] samples (t = 2.29; p = 0.02), which was older than the MEEI [4] sample (t = 4.22; p < 0.001). These differences can be attributed to the research questions being studied (e.g.…”

Section: Study Populationmentioning

confidence: 99%

Validation of a vision-related activity scale for patients with retinitis pigmentosa

Costela

Pesudovs

Sandberg

et al. 2020

Health Qual Life Outcomes

View full text Add to dashboard Cite

Purpose: There have been few systematic reports of vision-related activity limitations of people with retinitis pigmentosa (RP). We report a merging of data from the National Eye Institute Visual Function Questionnaire (NEI-VFQ) obtained in five previous studies. We asked whether the Vision Function Scale (VFS; Pesudovs et al., 2010) which was developed for cataract patients would apply in this new population (condition). Methods: Five hundred ninety-four individuals completed a total of 1753 questionnaires, with 209 participants providing responses over at least 4 years. Rasch analysis showed that the 15-item VFS was poorly targeted. A new instrument created by adding four driving-related items to the VFS had better targeting. As an indirect validation, VFS-plus person scores were compared to visual field area measured using a Goldmann perimeter, to the summed score for the combined 30-2 and 30/60-1 Humphrey Field Analyzer programs (HFA), to 30-Hz full-field cone electroretinogram (ERG) amplitude, and to ETDRS visual acuity. Changes in VFS-plus person scores with age and between four common heredity groups were also examined. Results: The Rasch model of responses to the 19 VFS-plus items had person and item separation of 2.66 and 24.43 respectively. The VFS-plus person scores were related to each vision measure (p < 0.001). Over a five-year period, there was a reduction in person scores of 0.5 logits (p < 0.001). Person scores fell by an average of 0.34 logits per decade (p < 0.0001). Participants with an X-linked hereditary pattern had, on average, lower person scores (p < 0.001). Conclusions: The VFS-plus instrument quantified a highly-significant annual reduction in perceived vision-related ability over a five-year period. The outcome was consistent with clinical measures of vision, and detected lower perceived vision-related ability in participants with X-linked disease. It may be of use in future studies, but this needs to be tested in a representative population sample.

show abstract

“…These include general quality of life questionnaires such as the WHO's WHOQOL [175,203], and SF-36 [124,242]. Vision-specific quality of life is assessed in more detail in patient-reported outcome measures such as the NEI-VFQ [167], independent mobility questionnaire [70], and the glaucoma-specific glaucoma symptom identifier [228] covering topics such as eye discomfort, drop side effects, and a variety of visual activities . It follows that we must take into account the effect of diagnosis and treatment on all aspects of physical, mental and social well-being when declaring treatment, a success in individual patients.…”

Section: Quality Of Life Indicatorsmentioning

confidence: 99%

Redefining clinical outcomes and endpoints in glaucoma

Yap

Normando

Cordeiro

2018

Expert Review of Ophthalmology

View full text Add to dashboard Cite

Introduction: Increasing life expectancy and ageing populations across the world are causing the number of glaucoma patients to rise dramatically. With longer lifespans also comes the need to improve the timeframe and accuracy with which we can diagnose, monitor and treat patients, ensuring longevity of vision contributes to a meaningful quality of life. Current markers used in glaucoma practice are in many cases suboptimal in their ability to accurately identify glaucomatous damage in time to prevent irreversible optic neuropathy. Areas covered: This review summarises the important properties of successful biomarkers and surrogates, and relates this to how intraocular pressure, visual field testing, and imaging have been refined to improve early diagnosis and progression analysis of glaucoma patients. Secondly, we discuss newer concepts in imaging, genetics, and objective measures which may provide biomarkers and surrogate endpoints with which to develop novel treatments in the future. Expert Commentary: We summarise the key relevant points in glaucoma research, and the current techniques being trialled that are most likely to lead to valuable biomarkers for the future.

show abstract

Rasch Analysis of the Independent Mobility Questionnaire

Cited by 5 publications

References 22 publications

A Scoping Review of Quality of Life Questionnaires in Glaucoma Patients

A Scoping Review of Quality of Life Questionnaires in Glaucoma Patients

Validation of a vision-related activity scale for patients with retinitis pigmentosa

Redefining clinical outcomes and endpoints in glaucoma

Contact Info

Product

Resources

About